Bio News
Phase 3 trial succeeds in patients with chronic thyroid eye disease Set to compete with Amgen’s Tepezza
Viridian Therapeutics’ thyroid eye disease treatment veligrotug recorded a response rate of up to 54% after 24 weeks in a phase 3 trial involving patients with chronic disease, showing a significant improvement over the placebo group (15%). The subcutaneous drug also improved diplopia symptoms by 61% in the once-monthly dosing group, higher than the placebo group’s 38%. The company plans to file for approval by the first quarter of next year to compete with Amgen’s Tepezza, a blockbuster with annual sales of $2 billion (approximately 2.9 trillion won).
BIOBOOK TEAM
biobookmedia@biobook.co.krMerck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
Ministry of Trade, Industry and Energy signs agreement to promote biotech and medical devices in Gangwon; site visit set for the 14th
RDA develops technology to produce anti-inflammatory exosomes for pets and files patent application
Merck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
